CYTK - サイトキネティクス （Cytokinetics Incorporated） サイトキネティクスCYTKのチャート
CYTKの企業情報
| symbol | CYTK |
|---|---|
| 会社名 | Cytokinetics Inc （サイトキネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サイトカイネティックス(Cytokinetics Incorporated)は後期バイオ医薬品会社である。同社は筋肉のパフォーマンスが損害あるいは低下などの衰弱性疾患の潜在的治療法としてのファースト・イン・クラス筋肉活性化因子の発見、開発、商業化などを行う。重病治療のために筋肉機能を調節する小分子治療法の発見と開発を中心とする。同社の臨床階段の薬品候補はtirasemtiv、CK-2127107とomecamtiv mecarbilを含む。同社は筋萎縮性側索硬化症（ALS）の治療のためのティラセミチブ薬候補を開発する。脊髄性筋萎縮、慢性閉塞性肺疾患およびALSの潜在的治療薬としてCK-2127107を開発する。Omecamtiv mecarbilは心不全の治療するための心筋ミオシンアクチベーターである。 サイトキネティクスは、米国の医薬品会社。心不全治療を適応とする医薬品薬候補の発見、開発、商業化に従事。主に、筋萎縮性側索硬化症に対する｢Tirasemtiv(正式名称：CK-2017357)｣の臨床試験に焦点を当てている。本社はカリフォルニア州サウスサンフランシスコ。 Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. |
| 本社所在地 | 280 East Grand Avenue South San Francisco CA 94080 USA |
| 代表者氏名 | Leonard Patrick Gage レナード・パトリック・ゲージ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-624-3000 |
| 設立年月日 | 35643 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2004年 |
| 従業員数 | 137人 |
| url | www.cytokinetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cytk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -112.14400 |
| 終値（lastsale） | 8.23 |
| 時価総額（marketcap） | 449588415.31 |
| 時価総額 | 時価総額（百万ドル） 429.92230 |
| 売上高 | 売上高（百万ドル） 17.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 230.34630 |
| 当期純利益 | 当期純利益（百万ドル） -130.64600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytokinetics Inc. revenues increased 59% to $11.5M. Net loss increased 5% to $57.8M. Revenues reflect Revenue Sales of Goods_Serv increase from $818K to $8.3M. Higher net loss reflects Research and development increase of 12% to $43.7M (expense) Non-cash interest expense on liability r increase of 41% to $8.5M (expense) General and administrative increase of 5% to $17.3M (expense). |
CYTKのテクニカル分析
CYTKのニュース
Cytokinetics Reports First Quarter 2020 Financial Results 2020/05/06 20:00:00 GlobeNewswire
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN…
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 2020/04/29 16:34:24 Zacks Investment Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript | The Motley Fool 2020/03/04 05:00:29 The Motley Fool
CYTK earnings call for the period ending January 31, 2020.
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering 2020/02/14 13:23:03 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release 2020/02/13 17:31:32 Zacks Investment Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Reports First Quarter 2020 Financial Results 2020/05/06 20:00:00 GlobeNewswire
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN…
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 2020/04/29 16:34:24 Zacks Investment Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript | The Motley Fool 2020/03/04 05:00:29 The Motley Fool
CYTK earnings call for the period ending January 31, 2020.
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering 2020/02/14 13:23:03 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release 2020/02/13 17:31:32 Zacks Investment Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript | The Motley Fool 2020/03/04 05:00:29 The Motley Fool
CYTK earnings call for the period ending January 31, 2020.
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering 2020/02/14 13:23:03 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release 2020/02/13 17:31:32 Zacks Investment Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO 2020/02/13 13:05:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: AGRX ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptose Biosciences Inc (NASDAQ: APTO ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Avrobio Inc (NASDAQ: AVRO ) Beam Therapeutics Inc (NASDAQ: BEAM ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) NeoGenomics, Inc. (NASDAQ: NEO ) Novartis AG (NYSE: NVS ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PAVmed Inc (NASDAQ: PAVM ) Penumbra Inc (NYSE: PEN ) Prevail Therapeutics Inc (NASDAQ: PRVL )(reacted to the FDA according Orphan Drug Designation to its experimental gene therapy PR001 for treating Gaucher disease) PTC Therapeutics, Inc (NASDAQ: PTCT ) Repligen Corporation (NASDAQ: RGEN ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc.
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data 2020/02/12 14:18:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …